Joseph Hargett

Joseph Hargett

Despite hailing from the Greater Cincinnati, Ohio area, Joseph Hargett has spent nearly the past decade elbow-deep in Wall Street.  Specializing in financial writing, options strategies and stock-market analysis, Joseph cut his teeth in the research department of Cincinnati-based Schaeffer’s Investment Research.

While at Schaeffer’s, Joseph wrote market, stock and options commentary for SchaeffersResearch.com, and was lead editor for The Options Advisor (the nation’s leading options newsletter).

Joseph has since moved on to become a prolific Forbes contributor in the options realm, as well as a lead copy editor and contributor for a well respected investment newsletter publisher.  Joseph’s commentary has appeared in a plethora of media outlets, including The Wall Street JournalThe New York TimesMoney Show Digest, Reuters, CBE MarketWatch and Sentiment Magazine.

Recent Articles

Thursday’s Vital Data: JD.com Inc(ADR) (JD), Time Warner Inc. (TWX) and Gilead Sciences, Inc. (GILD)

JD.com (JD) options rise as Stiffel resumes coverage, Time Warner (TWX) calls active amid AT&T (T) suit and Gilead (GILD) trades ex-dividend.

Alphabet Inc Looks Wimpish Heading Into 2018

Analysts are raising concerns about Alphabet's ad revenue growth, leaving GOOGL stock with few drivers heading into 2018.

Wednesday’s Vital Data: AT&T Inc (T), Comcast Corporation (CMCSA) and Tesla Inc (TSLA)

AT&T (T) options rise on tax plan hopes, Comcast (CMCSA) backs out of the Fox (FOXA) bidding war and Tesla (TSLA) gets 100 semi-truck order from Pepsi (PEP).

The Microsoft Corporation Bull Run Isn’t Over — Another 200% Gain Is Waiting

Microsoft is rebounding after testing key technical support. It's time to rid the bull run in MSFT stock higher heading into 2018.

Tuesday’s Vital Data: Tesla Inc (TSLA), Apple Inc. (AAPL) and Valeant Pharmaceuticals International, Inc. (VRX)

Tesla (TSLA) Model 3s at distribution centers, Apple (AAPL) options rise on Shazam and Valeant launches Vyzulta, eyes FDA on Luminesse.